Mr. Keith Cassidy reports

3D SIGNATURES INC. REPORTS Q1 FINANCIAL RESULTS

3D Signatures Inc. has released financial results for the three months ended Sept. 30, 2016. Amounts, unless specified otherwise, are expressed in accordance with international financial reporting standards. Consolidated condensed interim financial statements for the three-month period ended Sept. 30, 2016, and the management's discussion and analysis are available to be reviewed on SEDAR or the 3D Signatures website.

Corporate strategy

3D Signatures envisions itself as a developer of novel assays and a new class of biomarkers that it intends to license to commercial partners in key markets around the world. The company will expand the range of applications and markets through continuing research and development. 3D Signatures has assembled an accomplished team with successful records in the biomedical market and the development of laboratory developed tests and regulatory approval requirements.

3D Signatures has a balanced market entrance strategy, which combines a fast-track laboratory developed test (LTD) development to generate income, with a longer-term strategy to seek in vitro diagnostic device (IVDD) approval from Health Canada, the Food and Drug Administration (FDA), and European regulators. In addition to pursuing LDT and IVDD approvals for its tests, the company is actively engaging major biopharma companies in collaborations geared toward improving their drug-screening capabilities and developing companion diagnostics based on 3D Signatures' novel and proprietary platform. Development costs are being offset by grants and partnerships for efficient use of investment.

Selected interim financial information

The company has not earned revenues as of Nov. 29, 2016.

The attached table sets forth selected consolidated financial information for the three months ended Sept. 30, 2016. It has been derived from the company's consolidated condensed interim financial statements and accompanying notes, in each case prepared in accordance with IFRS. Its consolidated condensed interim financial statements have been reviewed by auditor MNP LLP. The selected financial information set out herein may not be indicative of 3D Signatures' future performance.

 
                   INCOME STATEMENT DATA

                          Three months ended Sept. 30, 2016  

Revenue                                               $0.00
Operating expenses                                3,367,898
(Loss) income                                    (3,367,898)

The company is also announcing it has retained Terry Bramhall, Clearcut Communications, a Vancouver-based investor relations service provider. Under the terms of the agreement, 3D Signatures will pay Clearcut a monthly fee of $2,000 for investor relations services. The agreement is for a term of six months.

About 3D Signatures

3D Signatures is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis chromosomal signatures. The technology is well developed and supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease. Depending on the desired application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient.

We seek Safe Harbor.